54.3 F
New York
Wednesday, October 28, 2020

Propanc Health Group Corp (OTCMKTS:PPCH) Gaining Traction on IP Catalysts

Must read

Guardant Health Inc. (NASDAQ:GH) Recent Earnings Shows Major Promise

Guardant Health Inc. (GH) shares are trading at higher $111.69 and the avg recommendation for the stock is Strong Buy, while the current analyst...

The Bank of Nova Scotia (NYSE:BNS) Stock is Plummeting, Here is Why

The Bank of Nova Scotia (BNS) shares are trading at lower $42.31 and the avg recommendation for the stock is Strong Buy, while the...

The Rejuvenation of First BanCorp. (NYSE:FBP)

First BanCorp. (FBP) shares are trading at lower $6.25 and the avg recommendation for the stock is Moderate Buy, while the current analyst price...

Renewed Optimism is Surrounding Takeda Pharmaceutical Company Limited (NYSE:TAK)

Takeda Pharmaceutical Company Limited (TAK) shares are trading at lower $16.55 and the avg recommendation for the stock is Moderate Buy, while the current...

Propanc Health Group Corp (OTCMKTS:PPCH) is a micro-cap name that has started to garner attention as the stock bounces up the chart. The recent move higher comes off a key pivot low and appears to be related to the company’s recent press: The company recently announced that it received a notification of allowance for its lead patent application from the US Patent Office. The patent application provides broad coverage for a method of treating a solid tumor through administering a pharmaceutical composition comprising a therapeutically effective amount of trypsinogen and chymotrypsinogen to patients.

Recent action has seen 28% tacked on to share pricing for the stock in the past week, but this action is running counter to the larger trend in the name. This is emblematic of the stock. PPCH is a stock whose past is littered with sudden rips. In addition, the company has benefitted from a jump in recent trading volume to the tune of just shy of 140% over the long run average.

Propanc Health Group Corp (OTCMKTS:PPCH) promulgates itself as a development stage healthcare company whose current focus is the development of new cancer treatments for patients with solid tumors such as pancreatic, ovarian and colorectal cancers. Propanc was established in 2007 and located in Melbourne, Australia.

According to company materials, “Propanc is developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes. In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening.”

Find out when $PPCH stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

As noted above, the company just announced that it recently received a notification of allowance for its lead patent application from the US Patent Office. The allowance of this key patent application is a first in the US, representing a major milestone for the Company as it progresses its lead product, PRP, a solution for once daily intravenous administration of pancreatic proenzymes, towards first-in-man studies in 2017. Further, the Company plans to file a continuation application with the US Patent Office to pursue additional claims based off the initial allowed application.

As we have discussed a number of times, intellectual property is the lifeblood of the biotechnology space. This type of announcement can turn out to be a truly meaningful shift in the narrative for a company like this one. Management voiced a similar sentiment in recent press.

“An allowance of a key patent application in the US is a significant event in the life of any company, particularly a biotech, and we are delighted to have achieved this milestone which provides broad protection for our lead product, PRP, for the treatment of solid tumors,” said James Nathanielsz, Propanc’s Chief Executive Officer. “We have filed numerous patent applications around the world in the past 12 to 18 months, with further applications expected. All of this represents a strong result for our shareholders who wait for progression of PRP into first-in-man studies this year. We firmly believe PRP is a new therapeutic approach for the treatment of metastatic cancer from solid tumors, which represents 80% of all cancers, and we are the leaders in this field of technology from an IP perspective, which is very exciting.”

Earning a current market cap value of $29.1M, PPCH has virtually no cash on the books, which must be weighed relative to about $487K in total current liabilities. The company is pre-revenue at this point. We will update the story again soon as further details emerge. For continuing coverage on shares of $PPCH stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

Latest article

Is Now the Time to Invest in AECOM (NYSE:ACM)?

AECOM (ACM) shares are trading at lower $44.33 and the avg recommendation for the stock is Strong Buy, while the current analyst price target...

GenMark Diagnostics Inc. (NASDAQ:GNMK) Stock is Soaring, Here is Why

GenMark Diagnostics Inc. (GNMK) shares are trading at higher $11.74 and the avg recommendation for the stock is Strong Buy. To add more color...

Oil States International Inc. (NYSE:OIS) is Holding Steady

Oil States International Inc. (OIS) shares are trading at lower $2.75 and the avg recommendation for the stock is Moderate Buy, while the current...

Investor Confidence is Falling for New Jersey Resources Corporation (NYSE:NJR)

New Jersey Resources Corporation (NJR) shares are trading at lower $30.51 and the avg recommendation for the stock is Moderate Buy, while the current...

Extended Stay America Inc. (NASDAQ:STAY) is Gaining Momentum on Earnings Catalyst

Extended Stay America Inc. (STAY) shares are trading at lower $11.35 and the avg recommendation for the stock is Moderate Buy, while the current...